Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine,Stavudine or Both

Manns M.P. , McHutchison J.G. , Gordon S.C. , Rustgi V.K. , Shiffman M. , Reindollar R. , Goodman Z.D. , Koury K. , Ling M. , & Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

Fried M.W. , Shiffman M.L. , Reddy K.R. , Smith C. , Marinos G. , Goncales F.L. Jr. , Haussinger D. , Diago M. , Carosi G. , Dhumeaux D. , Craxi A. , Lin A. , Hoffman J. , & Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347: 975–982.

Graham C.S. , Baden L.R. , Yu E. , Mrus J.M. , Carnie J. , Heeren T. , & Koziel M.J. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clinical Infectious Diseases 2001; 33: 562–569.

Di Martino V. , Rufat P. , Boyer N. , Renard P. , Degos F. , Martinot-Peignoux M. , Matheron S. , Le Moing V. , Vachon F. , Degott C. , Valla D. , & Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193–1199.

Quereda C. , Moreno L. , Moreno A. , Diaz S. , Barcena R. , Marti-Belda P. , Mateos M. , Pérez-Elias M. , Casado J. , & Moreno S. Early prediction of response to pegylated interferon-alfa 2b plus ribavirin in patients co-infected with HIV and HCV. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27–30 September 2002, San Diego, Calif., USA. Abstract H-1724.

Perronne C. , Carrat F. , Banisadr F. , Morand P. , Lunel F. , Roshental E. , & Pol S. Final results of ANRS HC02-RIBAVIC: A randomised controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. 11th Conference on Retroviruses & Opportunistic Infections. 8–11 February 2004. San Francisco, Calif., USA. Abstract 117LB.

Pérez-Olmeda M. , Núñez M. , Romero M. , González J. , Castro A. , Arribas J.R. , Pedreira J. , Barreiro P. , García-Samaniego J. , Martín-Carbonero L. , Jiménez-Nacher I. , & Soriano V. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023–1028.

Torriani F.J. , Rodriguez-Torres M. , Rockstroh J.K. , Lissen E. , Gonzalez-Garcia J. , Lazzarin A. , Carosi G. , Sasadeusz J. , Katlama C. , Montaner J. , Sette H. Jr. , Passe S. , De Pamphilis J. , Duff F. , Schrenk U.M. , & Dieterich D.T. ; A.P.R.I.C.O.T. Study Group. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV patients. New England Journal of Medicine 2004; 351: 438–450.

Lafeuillade A. , Hittinger G. , & Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280–281.

John M. , Moore C.B. , James I.R. , Nolan D. , Upton R.P. , McKinnon E.J. , & Mallal S.A. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717–723.

Delgado J. , Harris M. , Tesiorowski A. , & Montaner J. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clinical Infectious Diseases 2001; 33: 2072–2074.

Hartman N.R. , Ahluwalia G.S. , Cooney D.A. , Mitsuya H. , Kageyama S. , Fridland A. , Broder S. , & Johns D.G. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2'3′-dideoxyadenosine and 2'3′-dideoxyinosine. Molecular Pharmacology 1991; 40: 118–124.

Fleischer R. , Boxwell D. , & Sherman K.E. Nucleoside analogues and mitochondrial toxicity. Clinical Infectious Diseases 2004; 38: 79–80.

Côté H.C.F. , Brumme Z.L. , Craib K.J.P. , Math M. , Alexander C.S. , Wynhoven B. , Ting L. , Wong H. , Harris M. , Harrigan R. , O'Shaughnessy , & Montaner J. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346: 811–820.

Casademont J. , Miró O. , & Cardellach F. Mitochondrial DNA and nucleoside toxicity. New England Journal of Medicine 2002; 347: 216–218.

Miro O. , Lopez S. , Pedrol E. , Rodriguez-Santiago B. , Martinez E. , Soler A. , Milinkovic A. , Casademont J. , Nunes V. , Gatell J.M. , & Cardellach F. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antiviral Therapy 2003; 8: 333–338.

Pol S. , Carrat F. , Hor T.R. , Deshayes J. , Banisadr F. , Rosenthal E. , & Perronne C. High risk of mitochondriopathy in HIV/HCV co-infected patients under concomitant ddI/d4T and interferon (standard and pegylated IFN)/ribavirin treatments. 38th Annual Meeting of the European Association of the Study of the Liver. 3–6 July 2003, Geneva, Switzerland. Abstract 3530.00.

Ballesteros A.L. , Franco S. , Fuster D. , Planas R. , Martinez M.A. , Acosta L. , Sirera G. , Salas A. , Tor J. , Rey-Joly C. , Clotet B. , & Tural C. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 59–66.

Miró O. , Casademont J. , Barrientos A. , Urbano-Márquez A. , & Cardellach F. Mitochondrial cytochrome c oxydase inhibition during acute carbon monoxide poisoning. Pharmacology & Toxicology 1998; 82: 199–202.

Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods 2002; 26: 307–316.

López S. , Miró O. , Martínez E. , Pedrol E. , Rodríguez-Santiago B. , Milinkovic A. , Soler A. , García-Viejo M.A. , Núñez V. , Casademont J. , Gatell J.M. , & Cardellach F. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antiviral Therapy 2004; 9: 47–55.

Carr A. , Emery S. , Law M. , Puls R. , Lundgren J.D. , & Powderly W.G. ; H.I.V. Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726–735.

Walker U.A. , Setzer B. , & Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165–2173.

Brinkman K. , Smeitink J.A. , Romijn J.A. , & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999; 354: 1112–1115.

Brinkman K. , ter Hofstede H.J. , Burger D.M. , Smeitink J.A. , & Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–1744.

White A.J. Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections 2001; 77: 158–173.

Nolan D. , Hammond E. , James I. , McKinnon E. , & Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy 2003; 8: 617–626.

Moreno A. , Quereda C. , Moreno L. , Pérez-Elias M.J. , Muriel A. , Casado J.L. , Antela A. , Dronda F. , Navas E. , Bárcena R. , & Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy 2004; 9: 133–138.

Klein M.B. , Campeol N. , Lalonde R.G. , Brenner B. , & Wainberg M.A. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 2003; 17: 1001–1008.

John M. , Moore C.B. , James I.R. , Nolan D. , Upton R.P. , McKinnon E.J. , & Mallal S.A. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717–723.

Moyle G.J. , Datta D. , Mandalia S. , Morlese J. , Asboe D. , & Gazzard B.G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341–1349.

Brinkmann K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15: 795–797.

Boubaker K. , Flepp M. , Sudre P. , Furrer H. , Haensel A. , Hirschel B. , Boggian K. , Chave J.P. , Bernasconi E. , Egger M. , Opravil M. , Rickenbach M. , Francioli P. , & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clinical Infectious Diseases 2001; 33: 1931–1937.

Walker U.A. , Bäuerle J. , Laguno M. , Murillas J. , Mauss S. , Schmutz G. , Setzer B. , Miquel R. , Gatell J.M. , & Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311–317.

Mauss S. , Valenti W. , DePamphilis J. , Duff F. , Cupelli L. , Passe S. , Solsky J. , Torriani F.J. , Dieterich D. , & Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21–F25.

Cossarizza A. , & Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18: 137–151.

Lonergan J.T. , Behling C. , Pfander H. , Hassanein T.I. , & Mathews C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clinical Infectious Diseases 2000; 31: 162–166.

Mirshahi F. , Campbell-Sargent C. , Sterling R.K. , Luketic V.A. , Shiffman M. , Stravitz R.T. , & Sanyal A. Non-alcoholic steatohepatitis (NASH) is associated with hepatocytes mitochondrial DNA depletion. Hepatology 2002; 36: 403A.

Zaera M.G. , Miró O. , Pedrol E. , Soler A. , Picón M. , Cardellach F. , Casademont J. , & Nunes V. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15: 1643–1651.

Shikuma C.M. , Hu N. , Milne C. , Yost F. , Waslien C. , Shimizu S. , & Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801–1809.

Braü N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17: 2279–2290.